Corbus Pharmaceuticals Holdings Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Corbus Pharmaceuticals Holdings de 4.1% y 76.7% respectivamente, mientras que el BPA crecerá en un 19.8% al año.

Información clave

4.1%

Tasa de crecimiento de los beneficios

19.76%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.9%
Tasa de crecimiento de los ingresos	76.7%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Good
Última actualización	01 Jun 2026

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Artículo de análisis • May 20

We're Keeping An Eye On Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Seeking Alpha • Feb 06

Corbus Pharmaceuticals: Maintaining 'Hold' As Summer 2026 Obesity Data Catalyst Looms

Summary Corbus Pharmaceuticals maintains a 'Hold' rating as it advances CRB-701 for HNSCC and CRB-913 for obesity. CRBP expects to initiate a registrational CRB-701 study in mid-2026 and release 12-week CRB-913 obesity data in summer 2026. Early CRB-913 data show a 2.9% placebo-adjusted mean weight loss at Day 14 with a favorable safety profile and no nausea or vomiting. With $177.8M in cash post-raise, CRBP is funded into 2028, mitigating near-term dilution risk. Read the full article on Seeking Alpha

Artículo de análisis • Jul 07

Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Artículo de análisis • Mar 22

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Artículo de análisis • Dec 06

Companies Like Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, Corbus...

Seeking Alpha • Nov 11

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

Summary Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials and CRB-913 targeting obesity with potentially fewer CNS side effects. Despite early-stage pipeline risks, CRBP's recent sell-off offers a favorable entry point for speculative investors, upgrading my rating from "Hold" to "Speculative Buy." CRBP's valuation is compelling with $159.4 million in liquidity and no significant debt, providing a healthy cash runway. Market concerns over CNS side effects from similar drugs may be overblown. CRB-913's design aims to avoid these issues, enhancing its blockbuster potential. CRB-913, a CB1 inverse agonist for obesity, aims to reduce CNS side effects and presents potential for combination therapy with GLP-1 agonists. Read the full article on Seeking Alpha

Seeking Alpha • Jan 30

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:CRBP - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2028	3	-164	-143	-147	9
12/31/2027	2	-123	-106	-103	9
12/31/2026	1	-98	-96	-68	9
3/31/2026	N/A	-85	-74	-74	N/A
12/31/2025	N/A	-79	-64	-64	N/A
9/30/2025	N/A	-68	-60	-60	N/A
6/30/2025	N/A	-58	-58	-58	N/A
3/31/2025	N/A	-50	-50	-50	N/A
12/31/2024	N/A	-40	-42	-42	N/A
9/30/2024	N/A	-39	-37	-37	N/A
6/30/2024	N/A	-35	-30	-30	N/A
3/31/2024	N/A	-34	-29	-29	N/A
12/31/2023	N/A	-45	-36	-36	N/A
9/30/2023	N/A	-47	-38	-38	N/A
6/30/2023	N/A	-46	-38	-38	N/A
3/31/2023	N/A	-51	-42	-42	N/A
12/31/2022	N/A	-42	-38	-38	N/A
9/30/2022	N/A	-42	-40	-40	N/A
6/30/2022	0	-35	-32	-32	N/A
3/31/2022	0	-39	-37	-37	N/A
12/31/2021	1	-46	-48	-48	N/A
9/30/2021	2	-44	-57	-57	N/A
6/30/2021	3	-77	-85	-85	N/A
3/31/2021	3	-98	-94	-94	N/A
12/31/2020	4	-111	-100	-100	N/A
9/30/2020	6	-129	-106	-104	N/A
6/30/2020	7	-115	-97	-94	N/A
3/31/2020	36	-75	-87	-84	N/A
12/31/2019	36	-71	N/A	-46	N/A
9/30/2019	35	-62	N/A	-37	N/A
6/30/2019	34	-56	N/A	-29	N/A
3/31/2019	6	-70	N/A	-18	N/A
12/31/2018	5	-56	N/A	-30	N/A
9/30/2018	3	-49	N/A	-25	N/A
6/30/2018	3	-41	N/A	-23	N/A
3/31/2018	2	-37	N/A	-23	N/A
12/31/2017	2	-32	N/A	-28	N/A
9/30/2017	3	-29	N/A	-24	N/A
6/30/2017	3	-28	N/A	-21	N/A
3/31/2017	3	-25	N/A	-18	N/A
12/31/2016	2	-20	N/A	-14	N/A
9/30/2016	2	-15	N/A	-9	N/A
6/30/2016	1	-12	N/A	-8	N/A
3/31/2016	1	-10	N/A	-6	N/A
12/31/2015	1	-9	N/A	-5	N/A
9/30/2015	0	-8	N/A	-5	N/A
6/30/2015	0	-6	N/A	-3	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que CRBP siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que CRBP siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que CRBP siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (76.7% al año) de CRBP crezcan más rápidamente que los del mercado US (12.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (76.7% al año) de CRBP crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de CRBP se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2026/06/15 08:10
Precio de las acciones al final del día	2026/06/15 00:00
Beneficios	2026/03/31
Ingresos anuales	2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Corbus Pharmaceuticals Holdings, Inc. está cubierta por 22 analistas. 9 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Kalpit Patel	B. Riley Securities, Inc.
Mayank Mamtani	B. Riley Securities, Inc.
George Zavoico	B. Riley Securities, Inc.

Corbus Pharmaceuticals Holdings Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 7.4% to US$39.00

Price target increased by 8.2% to US$44.00

Price target decreased by 7.2% to US$42.89

Consensus EPS estimates upgraded to US$4.32 loss

Price target decreased by 9.9% to US$56.78

Price target decreased by 13% to US$71.00

Recent updates

Corbus Pharmaceuticals Holdings, Inc. Reports Updated Clinical Data For CRB-701 Phase 1/2 Study In Oropharyngeal And Cervical Cancers

Corbus Pharmaceuticals Holdings, Inc. Appoints Nishant Saxena as Chief Business Officer

New minor risk - Share price stability

We're Keeping An Eye On Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate

Corbus Pharmaceuticals Holdings Announces Updated Clinical Data From Phase 1/2 Study Of CRB-701 And Provides Update On CANYON-1 Phase 1b Study Of CRB-913

Price target decreased by 7.4% to US$39.00

Corbus Pharmaceuticals Holdings, Inc. Announces Updated Clinical Data for CRB-701 At ASCO 2026

Corbus Pharmaceuticals Holdings, Inc. Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity

Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Chief Medical Officer Dr. Dominic Smethurst, Effective June 30, 2026

Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 13, 2026

New major risk - Revenue and earnings growth

Chief Medical Officer notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Corbus Pharmaceuticals: Maintaining 'Hold' As Summer 2026 Obesity Data Catalyst Looms

Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Alan Holmer from its Board of Directors, Effective December 31, 2025

Corbus Pharmaceuticals Holdings, Inc. Reports Results from Phase 1A Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

New major risk - Shareholder dilution

Price target increased by 8.2% to US$44.00

Corbus Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $74.999901 million.

CEO & Director notifies of intention to sell stock

Corbus Pharmaceuticals Holdings, Inc. Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

Corbus Pharmaceuticals Holdings Inc. to Present CRB-701 Phase 1/2 Data At ESMO 2025

Corbus Pharmaceuticals Holdings, Inc. to Host In-Person and Virtual KOL Event At ESMO 2025

FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB -701 in Head and Neck Squamous Cell Carcinoma

Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for Its Nectin-4 Targeting Adc CRB -701 At the 2025 ESMO Annual Congress

Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) In A Good Position To Deliver On Growth Plans?

Corbus Pharmaceuticals Holdings Inc. Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted Cb1 Inverse Agonist Crb-913 for the Treatment of Obesity

Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) dropped from Russell 3000E Value Index

Corbus Pharmaceuticals Holdings, Inc. Announces First Patient Dosed with Its Nectin-4 Targeting ADC CRB-701 in Combination with Keytruda (Pembrolizumab)

Price target decreased by 7.2% to US$42.89

Corbus Pharmaceuticals Holdings, Inc. Announces Board Changes, Effective May 15, 2025

Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 15, 2025

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Is In A Good Position To Deliver On Growth Plans

Peter Salzmann Not to Stand for Re-Election as Director of Corbus Pharmaceuticals Holdings, Inc

Corbus Pharmaceuticals Holdings, Inc. Appoints Ian Hodgson as Chief Operating Officer

Consensus EPS estimates upgraded to US$4.32 loss

New minor risk - Market cap size

CEO & Director notifies of intention to sell stock

New minor risk - Share price stability

Corbus Pharmaceuticals Holdings, Inc. Presents Phase 1 Dose-Escalation Study of Next-Generation Nectin-4 Targeting Antibody-Drug Conjugate CRB-701

Corbus Pharmaceuticals Holdings, Inc. Announces Clinical Data for CRB-701 from Western Dose Escalation Study to Be Presented at ASCO GU 2025

Corbus Pharmaceuticals Announces Dosing of First Patient in Its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

Companies Like Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Are In A Position To Invest In Growth

Corbus Pharmaceuticals' CRB-701 Receives FDA Fast Track Designation for Metastatic Cervical Cancer Treatment

Price target decreased by 9.9% to US$56.78

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

Corbus Pharmaceuticals Holdings, Inc. Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024

Corbus Pharmaceuticals Holdings, Inc. Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Price target decreased by 13% to US$71.00

New major risk - Share price stability

Corbus Pharmaceuticals Holdings, Inc. Announces Board and Committee Changes

CEO & Director notifies of intention to sell stock

Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 16, 2024

Corbus Pharmaceuticals Holdings, Inc. Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Corbus Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Corbus Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Negative shareholders equity

Corbus Pharmaceuticals Holdings, Inc. Appoints Dominic Smethurst as Chief Medical Officer

Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Rachael Brake, Ph.D., as Chief Scientific Officer, Effective from February 19, 2024

New major risk - Shareholder dilution

Corbus Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $82.175 million.

New major risk - Shareholder dilution

Corbus Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering.

Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug

Corbus Pharmaceuticals Holdings, Inc. Announces Data from the First-in-Human Clinical Study of CRB-701 (SYS6002)

Nasdaq Gants Corbus Pharmaceuticals Holdings an Extension Until May 8, 2024 to Regain Compliance

Corbus Pharmaceuticals Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on The Nasdaq Capital Market, Under Listing Rule 5550(b)(1)

New minor risk - Share price stability